Table 1.
Baseline characteristics of the lab-confirmed SARS-CoV-2 positive patients and SARS-CoV-2 negative patients in the INSIGHT and OneFlorida+ cohorts, March 2020 to November 2021a
| INSIGHT | OneFlorida+ | |||||
|---|---|---|---|---|---|---|
| Characteristics | SARS-CoV-2 Positive (N = 35,275) | SARS-CoV-2 Negative (N = 326,126) | SMDb | SARS-CoV-2 Positive (N = 22,341) | SARS-CoV-2 Negative (N = 177,010) | SMDb |
| Median age (IQR)—years | 55 (38–68) | 57 (40–69) | −0.09 | 50 (34–64) | 57 (40–69) | −0.27 |
| Age group—no. (%) | ||||||
| 20-<40 years | 9529 (27.0) | 77,403 (23.7) | 0.08 | 7506 (33.6) | 42,286 (23.9) | 0.22 |
| 40-<55 years | 7975 (22.6) | 70,313 (21.6) | 0.03 | 5473 (24.5) | 37,555 (21.2) | 0.08 |
| 55-<65 years | 6965 (19.7) | 66,361 (20.3) | −0.02 | 4036 (18.1) | 37,142 (21.0) | −0.07 |
| 65-<75 years | 5712 (16.2) | 62,860 (19.3) | −0.08 | 2929 (13.1) | 34,601 (19.5) | −0.17 |
| 75+ years | 5094 (14.4) | 49,189 (15.1) | −0.02 | 2397 (10.7) | 25,426 (14.4) | −0.11 |
| Sex—no. (%) Female | 20,686 (58.6) | 196,730 (60.3) | −0.03 | 14,004 (62.7) | 106,963 (60.4) | 0.05 |
| Male | 14,586 (41.3) | 129,360 (39.7) | 0.03 | 8335 (37.3) | 70,034 (39.6) | −0.05 |
| Race—no. (%) Asian | 1736 (4.9) | 17,439 (5.3) | −0.02 | 275 (1.2) | 2912 (1.6) | −0.03 |
| Black | 7791 (22.1) | 62,281 (19.1) | 0.07 | 6504 (29.1) | 35,381 (20.0) | 0.21 |
| White | 12,233 (34.7) | 139,512 (42.8) | −0.17 | 11,398 (51.0) | 105,521 (59.6) | −0.17 |
| Other | 9844 (27.9) | 69,406 (21.3) | 0.15 | 3730 (16.7) | 30,138 (17.0) | −0.01 |
| Missing | 3671 (10.4) | 37,488 (11.5) | −0.03 | 434 (1.9) | 3058 (1.7) | 0.02 |
| Ethnic group—no. (%) | ||||||
| Hispanic | 10,658 (30.2) | 73,522 (22.5) | 0.17 | 4500 (20.1) | 21,484 (12.1) | 0.22 |
| Not Hispanic | 20,838 (59.1) | 216,179 (66.3) | −0.15 | 14,798 (66.2) | 120,315 (68.0) | −0.04 |
| Unknown | 3779 (10.7) | 36,425 (11.2) | −0.01 | 3043 (13.6) | 35,211 (19.9) | −0.17 |
| Median ADI (IQR)—rank | 15 (6–24) | 13 (5–23) | 0.03 | 58 (41–76) | 53 (36–72) | 0.19 |
| BMI kg/m2 (IQR) | 27 (21–32) | 25 (1–30) | 0.02 | 30 (25–35) | 28 (24–34) | 0.00 |
| Follow-up days (IQR) | 258 (163–418) | 269 (145–388) | 0.09 | 207 (109–367) | 250 (122–409) | −0.17 |
| Cares in the past 3 years—no. (%) | ||||||
| Inpatient 0 | 25,717 (72.9) | 278,784 (85.5) | −0.31 | 12,838 (57.5) | 112,480 (63.5) | −0.12 |
| Inpatient 1–2 | 6805 (19.3) | 37,297 (11.4) | 0.22 | 4614 (20.7) | 33,658 (19.0) | 0.04 |
| Inpatient >=3 | 2753 (7.8) | 10,045 (3.1) | 0.21 | 4889 (21.9) | 30,872 (17.4) | 0.11 |
| Corticosteroids Prescription | 4999 (14.2) | 28,915 (8.9) | 0.17 | 4253 (19.0) | 27,783 (15.7) | 0.09 |
| Immunosuppressant Prescriptions | 2110 (6.0) | 10,761 (3.3) | 0.13 | 1013 (4.5) | 7281 (4.1) | 0.02 |
| Index time—no. (%) | ||||||
| 03/20-06/20 | 11,235 (31.8) | 53,988 (16.6) | 0.36 | 2032 (9.1) | 37,363 (21.1) | −0.34 |
| 07/20-10/20 | 2018 (5.7) | 111,409 (34.2) | −0.76 | 6035 (27.0) | 54,060 (30.5) | −0.08 |
| 11/20-02/21 | 14,637 (41.5) | 88,009 (27.0) | 0.31 | 6254 (28.0) | 38,536 (21.8) | 0.14 |
| 03/21-06/21 | 5573 (15.8) | 54,234 (16.6) | −0.02 | 2315 (10.4) | 27,985 (15.8) | −0.16 |
| 07/21-11/21 | 1812 (5.1) | 18,486 (5.7) | −0.02 | 5705 (25.5) | 19,066 (10.8) | 0.39 |
aThe lab-confirmed SARS-CoV-2 positive and negative patients were identified by polymerase chain reaction (PCR) test or antigen test. Negative patients have further required no documented COVID-19-related diagnoses at baseline. IQR denotes the interquartile range. The percentage may not sum up to 100 because of rounding. ADI, the Area Deprivation Index. BMI, Body Mass Index.
bA standardized mean difference (SMD) of >0.10 or <−0.10 indicates an important effect size difference between the two samples, otherwise, no significant difference is assumed.